中国医院用药评价与分析2025，Vol.25Issue(5)：558-562,5.DOI:10.14009/j.issn.1672-2124.2025.05.010
复方苦参注射液联合安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究
Clinical Research on Compound Kushen Injection Combined with Anlotinib Capsules in the Treatment of Advanced Non-Small Cell Lung Carcinoma
摘要
Abstract
OBJECTIVE:To probe into the clinical efficacy and safety of compound Kushen injection combined with Anlotinib capsules in the treatment of advanced non-small cell lung carcinoma(NSCLC).METHODS:A total of 80 patients with advanced NSCLC admitted into the hospital from Jan.2022 to Jun.2023 were selected to be divided into observation group(received compound Kushen injection combined with Anlotinib capsules)and control group(received Anlotinib capsules alone)via random number table method,with 40 cases in each group.The clinical efficacy,quality of life scores,serum tumor markers,immune function indicator levels,incidences of adverse drug reactions and regular imaging follow-up for progression-free survival(PFS)of both groups were observed.RESULTS:After treatment,the disease control rate of the observation group was 90.00%(36/40),higher than 72.50%(29/40)of the control group,with statistically significant difference(P<0.05).After treatment,the observation group had better improvement in the score of quality of life measurement scale and longer PFS than the control group,and lower serum tumor markers for carcino-embryonic antigen,cytokeratin 19 fragment and squamous cell carcinoma-related antigen than the control group,with statistically significant differences(P<0.05).After treatment,the CD4+and CD4+/CD8+levels of observation group were higher than those of the control group,while the CD8+level was lower than that of the control group,with statistically significant differences(P<0.05).The incidences of adverse drug reactions of the observation group was 37.50%(15/40),which was lower than 65.00%(26/40)of the control group,with statistically significant difference(P<0.05).CONCLUSIONS:The combination of compound Kushen injection and Anlotinib capsules can promote the therapeutic effects and life quality of patients with advanced NSCLC,enhance patients'immune function and their tolerance to drug therapy.关键词
非小细胞肺癌/复方苦参注射液/安罗替尼胶囊/免疫功能Key words
Non-small cell lung cancer/Compound Kushen Injection/Anlotinib capsules/Immune function分类
药学引用本文复制引用
胡嘉芮,黄先涛,高楚淮,赵旭明,苏英鹏,樊捷婷,武晓媛,李占林..复方苦参注射液联合安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究[J].中国医院用药评价与分析,2025,25(5):558-562,5.基金项目
河北省中医药管理局科研计划项目(No.2022423) （No.2022423）
